Compare LEE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEE | PPCB |
|---|---|---|
| Founded | 1890 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 20.4M |
| IPO Year | N/A | N/A |
| Metric | LEE | PPCB |
|---|---|---|
| Price | $4.01 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 263.2K |
| Earning Date | 11-26-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $562,341,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.70 | $0.73 |
| 52 Week High | $16.84 | $145.46 |
| Indicator | LEE | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | N/A |
| Support Level | $3.90 | N/A |
| Resistance Level | $4.43 | N/A |
| Average True Range (ATR) | 0.38 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 2.73 | 0.00 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.